GCP
ENTX icon

GSA Capital Partners’s Entera Bio ENTX Stock Holding History

GSA Capital Partners’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,890
Closed -$23K – 1839
2025
Q4 		$23K Buy
+11,890
New +$27.9K ﹤0.01% 1599

Other funds holding ENTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SEIA
Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return

GSA Capital Partners's ENTX Position: Q1 2026 in Review

GSA Capital Partners sold out of Entera Bio (ENTX) in Q1 2026, closing a stake of 11,890 shares — an estimated $23K sold.

GSA Capital Partners first reported a position in ENTX in Q4 2025 and held it in 1 quarter. The position peaked at $23K in Q4 2025. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • GSA Capital Partners reported no remaining Entera Bio position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 11,890 Entera Bio shares in Q1 2026, an estimated $23K.
  • GSA Capital Partners first reported a position in Entera Bio in Q4 2025 and held it in 1 quarter.
  • GSA Capital Partners's Entera Bio position peaked at $23K in Q4 2025.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.